Scleroderma mimics

Current Rheumatology Reports

Volumn 14, Issue 1, 2012, Pages 39-46

  Nashel, Jennifer ^a   Steen, Virginia ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic cheiroarthropathy; Eosinophilic fasciitis; Lichen myxedematosus; Limited joint mobility syndrome; Localized scleroderma; Morphea; Nephrogenic systemic fibrosis; Scleredema; Scleredema adultorum; Scleredema diabeticorum; Scleredema of Buschke; Scleroderma mimics; Scleromyxedema

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYALURONIDASE; HYDROXYCHLOROQUINE; IMATINIB; IMMUNOGLOBULIN; LIDOCAINE; MELPHALAN; METHOTREXATE; PLACEBO; PREDNISONE; STEROID; TAMOXIFEN; THALIDOMIDE;

ARTHROPATHY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL FEATURE; DIABETIC CHEIROARTHROPATHY; DISEASE ASSOCIATION; DRUG MEGADOSE; EOSINOPHILIC FASCIITIS; HUMAN; IONIZING RADIATION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MORPHEA; MULTIPLE CYCLE TREATMENT; NEPHROGENIC SYSTEMIC FIBROSIS; OUTCOME ASSESSMENT; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PHYSIOTHERAPY; PLASMAPHERESIS; PROGNOSIS; PUVA; RADIOTHERAPY; SCLEREDEMA; SCLERODERMA; SCLEROMYXEDEMA; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

DIAGNOSIS, DIFFERENTIAL; EOSINOPHILIA; FASCIITIS; HUMANS; NEPHROGENIC FIBROSING DERMOPATHY; SCLEREDEMA ADULTORUM; SCLERODERMA, LOCALIZED; SCLEROMYXEDEMA;

EID: 84857058145     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0220-8     Document Type: Article

References (37)

1. • Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64(2):217-28. This is an excellent review of the spectrum of morphea and localized scleroderma.
2. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2005.
3. • Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011; 64(2):231-42. This is an important summary on the direction in which outcome measures and treatment of localized scleroderma are moving.
4. • Wortsman X, Gutierrez M, Saavedra T, Honeyman J. The role of ultrasound in rheumatic skin and nail lesions: a multi-specialist approach. Clin Rheumatol 2011; 30(6):739-48. This is a discussion of the use of ultrasound in evaluation of scleroderma skin.
5. EB Kroft MC Creemers FH van den Hoogen JB Boezeman EM de Jong 2009 Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study Br J Dermatol 160 5 1075 1082 19210503 10.1111/j.1365-2133.2008.09017.x 1:CAS:528:DC%2BD1MXlvFOis7w%3D
6. • Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011; 63(7):1998-2006. This is an excellent example of how a randomized controlled trial can be carried out in this rare disease.
7. A Kreuter J Hyun M Stucker A Sommer P Altmeyer T Gambichler 2006 A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma J Am Acad Dermatol 54 3 440 447 16488295 10.1016/j.jaad.2005.11.1063 (Pubitemid 43243447)
8. A Kreuter J Hyun M Skrygan A Sommer NS Tomi F Breuckmann, et al. 2006 Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma Arch Dermatol Res 298 6 265 272 17009056 10.1007/s00403-006-0695-8 1:CAS:528:DC%2BD28XhtVagsrzL (Pubitemid 44484444)
9. A Kreuter J Hyun M Skrygan A Sommer A Bastian P Altmeyer, et al. 2006 Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma Br J Dermatol 155 3 600 607 16911288 10.1111/j.1365-2133.2006.07391.x 1:CAS:528:DC%2BD28XhtVOqtLfI (Pubitemid 44215493)
10. WH Beers A Ince TL Moore 2006 Scleredema adultorum of Buschke: a case report and review of the literature Semin Arthritis Rheum 35 6 355 359 16765712 10.1016/j.semarthrit.2006.01.004 (Pubitemid 43831155)
11. M Dziadzio CP Anastassiades PN Hawkins M Potter A Gabrielli GM Brough, et al. 2006 From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature Clin Rheumatol 25 1 3 15 15742120 10.1007/s10067-004- 1076-3
12. C Meguerditchian P Jacquet S Beliard T Benderitter R Valero F Carsuzza, et al. 2006 Scleredema adultorum of Buschke: an under recognized skin complication of diabetes Diabetes Metab 32 5 Pt 1 481 484 17110904 10.1016/S1262-3636(07)70307-5 1:STN:280:DC%2BD28nnt1KmtQ%3D%3D (Pubitemid 44836591)
13. Y Ikeda T Suehiro T Abe T Yoshida T Shinoki K Tahara, et al. 1998 Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin E1 Intern Med 37 10 861 864 9840709 10.2169/ internalmedicine.37.861 1:STN:280:DyaK1M%2FlsVCntg%3D%3D (Pubitemid 28550636)
14. N Thumpimukvatana C Wongpraparut HW Lim 2010 Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy J Dermatol 37 12 1036 1039 21083706 10.1111/j.1346-8138.2010.01014.x
15. SH Alsaeedi P Lee 2010 Treatment of scleredema diabeticorum with tamoxifen J Rheumatol 37 12 2636 2637 21123339 10.3899/jrheum.100561
16. AL Rosenbloom 1989 Limitation of finger joint mobility in diabetes mellitus J Diabet Complications 3 2 77 87 2526144 10.1016/0891-6632(89)90016-0 1:STN:280:DyaL1MzgvV2ktQ%3D%3D
17. AL Rosenbloom 1989 Diabetic thick skin and stiff joints Diabetologia 32 1 74 76 2707519 10.1007/BF00265408 1:STN:280:DyaL1M3htFKltw%3D%3D
18. M Blum FM Wigley LK Hummers 2008 Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG) Medicine (Baltimore) 87 1 10 20 10.1097/MD.0b013e3181630835
19. JJ Pomann EJ Rudner 2003 Scleromyxedema revisited Int J Dermatol 42 1 31 35 12581140 10.1046/j.1365-4362.2003.01565.x (Pubitemid 41709816)
20. F Rongioletti A Rebora 2001 Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema J Am Acad Dermatol 44 2 273 281 11174386 10.1067/mjd.2001.111630 1:STN:280:DC%2BD3M7kvF2gsw%3D%3D (Pubitemid 32172190)
21. AM Dinneen CH Dicken 1995 Scleromyxedema J Am Acad Dermatol 33 1 37 43 7601944 10.1016/0190-9622(95)90007-1 1:STN:280:DyaK2MzisFChuw%3D%3D
22. ML Donato AM Feasel DM Weber VG Prieto SA Giralt RE Champlin, et al. 2006 Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation Blood 107 2 463 466 16179379 10.1182/blood-2004-12-4870 1:CAS:528:DC%2BD28Xms1emsA%3D%3D (Pubitemid 43076365)
23. M Laimer K Namberger C Massone J Koller M Emberger L Pleyer, et al. 2009 Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema Acta Derm Venereol 89 6 631 635 19997697 10.2340/00015555-0731 1:CAS:528: DC%2BC3cXitVWhsbg%3D
24. SE Cowper HS Robin SM Steinberg LD Su S Gupta PE LeBoit 2000 Scleromyxoedema-like cutaneous diseases in renal-dialysis patients Lancet 356 9234 1000 1001 11041404 10.1016/S0140-6736(00)02694-5 1:STN:280: DC%2BD3cvptVWgsw%3D%3D
25. • Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: a review of experimental data. World J Radiol 2010; 2(11):427-33. This is an important summary of the relationship of gadolinium to NSF.
26. J Perez-Rodriguez S Lai BD Ehst DM Fine DA Bluemke 2009 Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases Radiology 250 2 371 377 19188312 10.1148/radiol.2502080498
27. G Schieren N Wirtz P Altmeyer LC Rump SM Weiner A Kreuter 2009 Nephrogenic systemic fibrosis-a rapidly progressive disabling disease with limited therapeutic options J Am Acad Dermatol 61 5 868 874 19836645 10.1016/j.jaad.2009.03.040
28. P Marckmann L Skov 2009 Nephrogenic systemic fibrosis: clinical picture and treatment Radiol Clin North Am 47 5 833 840 19744598 10.1016/j.rcl.2009.05. 004 vi
29. A Kreuter T Gambichler SM Weiner G Schieren 2008 Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis Arch Dermatol 144 11 1527 1529 19015438 10.1001/archderm.144.11.1527
30. J Kay WA High 2008 Imatinib mesylate treatment of nephrogenic systemic fibrosis Arthritis Rheum 58 8 2543 2548 18668587 10.1002/art.23696 1:CAS:528:DC%2BD1cXhtVCjur7J
31. MC Cuffy M Singh R Formica E Simmons AK Abu Alfa K Carlson, et al. 2011 Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature Nephrol Dial Transplant 26 3 1099 1101 21079195 10.1093/ndt/gfq693
32. LE Shulman 1975 Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 88 70 86 1224441 1:STN:280:DyaE287nvFalsQ%3D%3D
33. M Antic S Lautenschlager PH Itin 2006 Eosinophilic fasciitis 30 years after-what do we really know? Report of 11 patients and review of the literature Dermatology 213 2 93 101 16902285 10.1159/000093847 (Pubitemid 44215192)
34. L Bischoff CT Derk 2008 Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature Int J Dermatol 47 1 29 35 18173597 10.1111/j.1365-4632.2007.03544.x
35. M Fujimoto S Sato H Ihn K Kikuchi N Yamada K Takehara 1995 Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis J Rheumatol 22 3 563 565 7783084 1:STN:280:DyaK2Mzgt1eluw%3D%3D
36. F Baumann P Bruhlmann G Andreisek BA Michel B Marincek D Weishaupt 2005 MRI for diagnosis and monitoring of patients with eosinophilic fasciitis AJR Am J Roentgenol 184 1 169 174 15615969 (Pubitemid 40040923)
37. L Barnes GP Rodnan TA Medsger 1979 Short D. Eosinophilic fasciitis. A pathologic study of twenty cases Am J Pathol 96 2 493 518 474708 1:STN:280:DyaE1M3ltlalsg%3D%3D